Simplify diabetes management for your patients

Healthcare providers (HCPs) like you who care for people with diabetes are talking with more and more patients who are interested in the benefits of an insulin pump. Among Canadian HCPs, complexity is the #1 reason that pumps are not recommended for some patients.1

Pod Therapy is something you might consider instead.

Omnipod® provides a simple, effective alternative to both MDI and tubed pumps
for patients requiring insulin.


One small, tubeless, wearable, and waterproof* Pod provides up to 3 days (72 hours) of non-stop insulin.

*The Pod has an IP28 rating for up to 7.6 metres (25 feet) for 60 minutes.
The Personal Diabetes Manager is not waterproof.

Actual Pod size: 3.9 cm wide x 5.2 cm long x 1.45 cm high

Omnipod® Products

Omnipod DASH®
Insulin Management System

The discreet, tubeless and waterproof* way to deliver insulin for your patients

*The Pod has an IP28 rating for up to 7.6 metres (25 feet) for 60 minutes. The Personal Diabetes Manager is not waterproof.

Insulin Management System

The original Omnipod® System with built-in FreeStyle® Lite blood glucose meter

Pod therapy can simplify diabetes management for your patients

Give them the benefits of tubeless freedom.

They get a 2 part management system that is: 
- tubeless
- waterproof
- replaces 14 daily needle injections with continuous insulin delivery for up to 3 days (72 hours)

*The Pod has an IP28 rating for up to 7.6 metres (25 feet) for 60 minutes. The Personal Diabetes Manager (PDM) is not waterproof.

Other system benefits include:

  • Simple to set up and train patients
  • Quick access to patient data from anywhere with Glooko®
  • Intuitive screen navigation and quick treatment modifications
  • 99% of users chose to stay on Omnipod® Insulin Management System therapy after 3 years2
  • Virtually pain-free automated cannula insertion

Have a patient ready to experience the tubeless freedom of Omnipod®?

“ The Pod is a revolution in insulin therapy. No tubes, less needle sticks, constant insulin delivery for 3 days — no disconnect. All of these factors improve adherence among people with diabetes and, as a result, dramatically improve clinical outcomes and quality of life.

Dr. Michael R. Brennan D.O., M.S., F.A.C.E., F.A.C.P.,
is an award-winning endocrinology, diabetes and metabolism specialist and founder of the Beaumont Endocrine Center

Dr. Brennan is a paid consultant of Insulet Corporation, however, the views expressed in this testimony are his own.


1. Data on File, Insulet Canada, 2022.
2. Leelarathna L., et al. Diabet Med. 2017;34(10):1372–1379. Observational, retrospective study which was evaluated long-term HbA1c changes on insulin pump therapy (Medtronic, Insulet, Roche and Animas). 508 individuals starting pump therapy, 94% had type 1 diabetes. Median follow-up was 3.7 years. Study conducted in UK.

FreeStyle and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions and used with permission.

Regional Disclaimer

Are you a resident of Canada?

Yes No

The content of the webpage that you are about to access is exclusively reserved for residents of Canada.

If you are a resident of Canada, please click 'Yes' to continue. If not, please click 'No' to exit and do not access the webpages. If you selected this country/language in error, you can go back to the previous page and select your country/language.

Thank you.

Please verify that you are a Healthcare Professional.

The content on this section of our website is intended for Canadian Healthcare Professionals only.

If you are not a Canadian Healthcare Professional, you will be redirected to the Omnipod® Homepage.

License number is required.